Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis.
Structural mechanism for statin inhibition of HMG-CoA reductase.
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
Characteristics of persons with overactive bladder of presumed neurologic origin: Results from the boston area community health (BACH) survey.
Motor vehicle operation in the setting of multiple sclerosis with myelopathy: assessment, adaptive equipment, counseling, and cessation of driving.
T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.
Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Dual-Task Assessment in Natalizumab-Treated Multiple Sclerosis Patients.
Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations.
Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs.
Do not treat from CIS onset: evaluate disease course and prognosis first - No (treat!).
[Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis].
Neuroprotection in Huntington's disease: a 2-year study on minocycline.
Acid-sensing ion channels: trafficking and synaptic function.
Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
Psychiatric disorders in patients with multiple sclerosis.
A CB(1)/CB(2) receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin.
Gammaherpesvirus Latency Accentuates EAE Pathogenesis: Relevance to Epstein-Barr Virus and Multiple Sclerosis.
Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway.
Impact of acupuncture by using life-energy (qi) oriental needle on the paralysis of rats with experimental autoimmune encephalomyelitis.
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.
Increased risk of multiple sclerosis relapse after in vitro fertilisation.
The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy.
Pages
« first
‹ previous
…
166
167
168
169
170
171
172
173
174
…
next ›
last »